EI
Therapeutic Areas
Crescent Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Next-Gen IO Bispecific (e.g., PD-1 x VEGF) | Solid Tumors | Phase 1 |
| Improved ADC Candidates | Solid Tumors | Not Disclosed |
| Synergistic Combination Regimens | Solid Tumors | Not Disclosed |
Leadership Team at Crescent Biopharma
JB
Joshua Brumm
Chief Executive Officer
JM
Jonathan McNeill, M.D.
President and Chief Operating Officer
RS
Rick Scalzo
Chief Financial Officer
JP
Jan Pinkas, Ph.D.
Chief Scientific Officer
BB
Barbara Bispham
General Counsel
RL
Ryan Lynch
Senior Vice President, Finance and Chief Accounting Officer
CD
Chris Doughty
Chief Business Officer
AR
Amy Reilly
Chief Communications Officer
TS
Tanya Sengupta
Executive Vice President, Chief of Strategy and Operations
WC
Wenjie Cheng, Ph.D.
Senior Vice President, Technical Operations